Founded in 1997, Chengdu Rongsheng is a core subsidiary of BTBP. In 2001, Chengdu Institute of Biological Products Co., Ltd has transferred its blood product business to Chengdu Rongsheng. In the early 1980s, Chengdu Rongsheng established the first batch of plasmapheresis centers nationwide. With rich experience in source plasma management, Chengdu Rongsheng was the first to start industrial production of blood products in China, securing numerous firsts in the domestic blood product industry. In 2008, it has been recognized as a high-tech enterprise; In 2019, it was awarded the title of "Sichuan Province Brand Value Benchmark Enterprise".

The "Rongsheng" brand blood product have dominated the Chinese blood product market with its comprehensive advantages in quality, safety, market share, and brand value for decades. It has also been praised by the Ministry of Health as a "model of blood products". The market sales of "Rongsheng" IVIG have ranked first in the country for consecutive years, and the cumulative clinical use of "Rongsheng" human albumin has exceeded 23 million times.